No significant change seen in unfavorable neurologic outcome as assessed by score on GOS-E at six months

Improved progression-free survival seen for amivantamab-lazertinib versus osimertinib as first-line treatment

Prophylaxis recommended over episodic treatment of bleeding events for severe and moderately severe hemophilia A and B

24.9 percent received creatinine and UACR screening; Hispanic ethnicity associated with lack of screening

Age, gender, hypertension, and alcohol consumption may influence the association

Findings for sound stimulation of 75 dB at a frequency of 100 Hz

Income and area-level disadvantage are the largest contributors to racial differences

Higher risk seen for gaining weight with escitalopram, paroxetine, duloxetine; lower risk with bupropion

Adolescents who experience moderately and highly insecure housing have reduced odds of excellent health